Jacobs Levy Equity Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Jacobs Levy Equity Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-293,500	Closed	-$3.16M	–	1031
2023 Q1	$3.16M	Sell	293,500 -30,237	-9%	-$398K	0.02%	482
2022 Q4	$4.85M	Buy	323,737 +6,291	+2%	+$91.6K	0.03%	401
2022 Q3	$4.08M	Buy	+317,446	New	+$3.62M	0.03%	434
2021 Q3	–	Sell	-47,178	Closed	-$657K	–	1086
2021 Q2	$657K	Sell	47,178 -3,335	-7%	-$50.7K	﹤0.01%	819
2021 Q1	$935K	Buy	50,513 +11,119	+28%	+$227K	0.01%	751
2020 Q4	$696K	Sell	39,394 -2,386	-6%	-$41.9K	0.01%	804
2020 Q3	$640K	Sell	41,780 -3,377	-7%	-$63.4K	0.01%	744
2020 Q2	$1.15M	Sell	45,157 -4,367	-9%	-$91.2K	0.01%	641
2020 Q1	$767K	Sell	49,524 -8,103	-14%	-$127K	0.01%	685
2019 Q4	$637K	Buy	+57,627	New	+$501K	0.01%	756

Other funds holding KNSA

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Jacobs Levy Equity Management's KNSA Position: Q2 2023 in Review

Jacobs Levy Equity Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2023, closing a stake of 293,500 shares — an estimated $3.16M sold.

Jacobs Levy Equity Management first reported a position in KNSA in Q4 2019 and held it in 10 quarters. The position peaked at $4.85M in Q4 2022. 127 funds tracked by Wall St. Rank hold KNSA as of Q2 2023.

Jacobs Levy Equity Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Jacobs Levy Equity Management sold 293,500 Kiniksa Pharmaceuticals shares in Q2 2023, an estimated $3.16M.
Jacobs Levy Equity Management first reported a position in Kiniksa Pharmaceuticals in Q4 2019 and held it in 10 quarters.
Jacobs Levy Equity Management's Kiniksa Pharmaceuticals position peaked at $4.85M in Q4 2022.
127 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2023, filed 14 Aug 2023.